These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 2975406)
21. Altered serum factor VIII-related antigen (VIII : AGN)/von Willebrand factor (VIII : vWf) in haemophiliacs with inhibitors to factor VIII procoagulant activity (VIII : C). Ballard JO; Sanders JC; Eyster ME Thromb Haemost; 1981 Feb; 45(1):68-72. PubMed ID: 6166064 [TBL] [Abstract][Full Text] [Related]
22. Further evidence of von Willebrand factor involvement in thrombotic thrombocytopenia purpura. Chediak J; Eldridge J; Bergmann F; Sobel D; Baron J; Maxey B; Telfer MC Thromb Haemost; 1988 Aug; 60(1):13-7. PubMed ID: 3263710 [TBL] [Abstract][Full Text] [Related]
23. Seminal Factor VIII and von Willebrand Factor: a possible role of the conventional clotting system in human semen? Lwaleed BA; Greenfield R; Royle E; Birch B; Cooper AJ Int J Androl; 2005 Feb; 28(1):31-8. PubMed ID: 15679619 [TBL] [Abstract][Full Text] [Related]
24. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Rumley A; Lowe GD; Sweetnam PM; Yarnell JW; Ford RP Br J Haematol; 1999 Apr; 105(1):110-6. PubMed ID: 10233372 [TBL] [Abstract][Full Text] [Related]
25. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Eikenboom JC; Castaman G; Kamphuisen PW; Rosendaal FR; Bertina RM Thromb Haemost; 2002 Feb; 87(2):252-7. PubMed ID: 11859851 [TBL] [Abstract][Full Text] [Related]
26. The hemostatic profiles of patients with Type O and non-O blood after acute normovolemic hemodilution with 6% hydroxyethyl starch (130/0.4). Kang JG; Ahn HJ; Kim GS; Hahm TS; Lee JJ; Gwak MS; Choi SJ Anesth Analg; 2006 Dec; 103(6):1543-8. PubMed ID: 17122237 [TBL] [Abstract][Full Text] [Related]
27. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107 [TBL] [Abstract][Full Text] [Related]
28. Molecular genetics of von Willebrand disease. Mazurier C; Ribba AS; Gaucher C; Meyer D Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650 [TBL] [Abstract][Full Text] [Related]
29. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Aukrust P; Bjørnsen S; Lunden B; Otterdal K; Ng EC; Ameln W; Ueland T; Müller F; Solum NO; Brosstad F; Frøland SS Thromb Haemost; 2000 Aug; 84(2):183-7. PubMed ID: 10959687 [TBL] [Abstract][Full Text] [Related]
30. In vitro characterization of various factor VIII concentrates. Yoshioka A; Shima M; Nishino M; Yoshikawa N; Fukui H Arzneimittelforschung; 1987 Jul; 37(7):753-6. PubMed ID: 3118888 [TBL] [Abstract][Full Text] [Related]
31. The von Willebrand factor in myocardial infarction and unstable angina: a kinetic study. Margulis T; David M; Maor N; Soff GA; Grenadier E; Palant A; Aghai E Thromb Haemost; 1986 Jun; 55(3):366-8. PubMed ID: 3092393 [TBL] [Abstract][Full Text] [Related]
32. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor. Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA; Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481 [TBL] [Abstract][Full Text] [Related]
34. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
35. The interaction of the factor VIII/von Willebrand factor complex with hematin. Green D; Furby FH; Berndt MC Thromb Haemost; 1986 Dec; 56(3):277-82. PubMed ID: 3105105 [TBL] [Abstract][Full Text] [Related]
36. Reactivity of small molecular forms of human factor VIII/von Willebrand factor with botrocetin and anti-factor VIII-coated latex particles. Furlan M; Perret BA; Beck EA Thromb Haemost; 1985 Aug; 54(2):463-5. PubMed ID: 3936216 [TBL] [Abstract][Full Text] [Related]
37. [Activation of endothelium-dependent hemostatic factors following bone marrow transplantation]. Tsakiris DA; Marbet GA; Tichelli A; Gratwohl A; Speck B Schweiz Med Wochenschr; 1995 Mar; 125(9):416-9. PubMed ID: 7892569 [TBL] [Abstract][Full Text] [Related]
38. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Murdock PJ; Woodhams BJ; Matthews KB; Pasi KJ; Goodall AH Thromb Haemost; 1997 Oct; 78(4):1272-7. PubMed ID: 9364997 [TBL] [Abstract][Full Text] [Related]
39. The heparin-von Willebrand factor interaction and conventional tests of haemostasis - the challenges in predicting bleeding in cardiopulmonary bypass. Ranger A; Gaspar M; Elkhatteb A; Jackson T; Fox S; Aw TC; Vipond L; Cotterill J; Ghori A; Laffan M; Arachchillage DRJ Br J Haematol; 2021 Mar; 192(6):1073-1081. PubMed ID: 33278841 [TBL] [Abstract][Full Text] [Related]
40. Release of von Willebrand factor by cardiopulmonary bypass, but not by cardioplegia in open heart surgery. Valen G; Blombäck M; Sellei P; Lindblom D; Vaage J Thromb Res; 1994 Jan; 73(1):21-9. PubMed ID: 8178310 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]